Development and collapse of an Oscillatoria bloom in Loch Leven during July 1994

During 1994, weekly spot-sampling of open water sites on Loch Leven took place from 16th March onwards. Very little difference between spot-sampling sites was observed from 16th March to 5th July. Throughout April and May there was a slow increase in levels of chlorophyll-a, followed by a rapid increase through June, reaching a maximum of 230 micrograms per litre. On 8th July there was a very rapid rise in water temperature, with a corresponding increase in dissolved oxygen and pH. At 0915 hours on 9th July there was a drop in all three variables. These changes were coincident with a marked reduction in chlorophyll-a values falling to 70 micrograms per litre on 12th July. On 16th July evidence of a resurgence of photosynthesis was observed

The Sodium Channel as a Target for Local Anesthetic Drugs

Na channels are the source of excitatory currents for the nervous system and muscle. They are the target for a class of drugs called local anesthetics (LA), which have been used for local and regional anesthesia and for excitatory problems such as epilepsy and cardiac arrhythmia. These drugs are prototypes for new analgesic drugs. The drug-binding site has been localized to the inner pore of the channel, where drugs interact mainly with a phenylalanine in domain IV S6. Drug affinity is both voltage- and use-dependent. Voltage-dependency is the result of changes in the conformation of the inner pore during channel activation and opening, allowing high energy interaction of drugs with the phenylalanine. LA drugs also reduce the gating current of Na channels, which represents the movement of charged residues in the voltage sensors. Specifically, drug binding to phenylalanine locks the domain III S4 in its outward (activated) position, and slows recovery of the domain IV S4. Although strongly affecting gating, LA drugs almost certainly also block by steric occlusion of the pore. Molecular definition of the binding and blocking interactions may help in new drug development

The restoration of Loch Leven, Scotland, UK

This paper reviews the progress made towards the restoration of Loch Leven, the largest lake in lowland Scotland, over the last 20 years. In particular, the importance of direct regulation and of setting water quality objectives and targets is examined. Various means of engaging with stakeholders and the general public are also considered. Success criteria and catchment management initiatives are described and briefly reviewed

Development and collapse of an Oscillatoria bloom in Loch Leven during July 1994

Loch Leven lies in a glacial depression 35 kilometres north of Edinburgh,Scotland. It has a large surface area, 13.3 km², but is generally shallowwith a mean depth of 3.9 metres, although there are two deeper "holes"where the depth reaches 25 metres. Land use in the 145 km² catchmentdraining to the loch is predominantly arable farming, with some roughgrazing in the headwaters and with three small towns close to the loch.The physical characteristics of Loch Leven are fully described by Smith(1974); it is a National Nature Reserve, a Site of Special ScientificInterest, and is cited under the Ramsar Convention as a wetland site ofinternational importance

Glutamine repeat variants in human RUNX2 associated with decreased femoral neck BMD, broadband ultrasound attenuation and target gene transactivation

RUNX2 is an essential transcription factor required for skeletal development and cartilage formation. Haploinsufficiency of RUNX2 leads to cleidocranial displaysia (CCD) a skeletal disorder characterised by gross dysgenesis of bones particularly those derived from intramembranous bone formation. A notable feature of the RUNX2 protein is the polyglutamine and polyalanine (23Q/17A) domain coded by a repeat sequence. Since none of the known mutations causing CCD characterised to date map in the glutamine repeat region, we hypothesised that Q-repeat mutations may be related to a more subtle bone phenotype. We screened subjects derived from four normal populations for Q-repeat variants. A total of 22 subjects were identified who were heterozygous for a wild type allele and a Q-repeat variant allele: (15Q, 16Q, 18Q and 30Q). Although not every subject had data for all measures, Q-repeat variants had a significant deficit in BMD with an average decrease of 0.7SD measured over 12 BMD-related parameters (p = 0.005). Femoral neck BMD was measured in all subjects (&minus;0.6SD, p = 0.0007). The transactivation function of RUNX2 was determined for 16Q and 30Q alleles using a reporter gene assay. 16Q and 30Q alleles displayed significantly lower transactivation function compared to wild type (23Q). Our analysis has identified novel Q-repeat mutations that occur at a collective frequency of about 0.4%. These mutations significantly alter BMD and display impaired transactivation function, introducing a new class of functionally relevant RUNX2 mutants.<br /